BridgeBio Pharma Presents Cardiac Magnetic Resonance (CMR) Imaging Evidence Consistent with Clinical Improvement Observed in the ATTRibute-CM Phase 3 Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
First Patient Randomized in AskBio Phase II Gene Therapy Trial for Congestive Heart Failure streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
AB-1002 is an investigational gene therapy for the treatment of adults with non-ischemic cardiomyopathy and New York Heart Association (NYHA) Class III heart failure symptoms1GenePHIT is a clinical trial to evaluate the safety and efficacy of the one-time administration of AB-1002 and will include the largest number.
- Phase 3 open-label, single-arm study conducted in Japan by BridgeBio licensing partner Alexion, AstraZeneca Rare Disease showed consistency with global ATTRibute-CM Phase III trial - No mortality.
- ATTRibute-CM demonstrated a significant treatment effect of acoramidis on the primary endpoint and frequency of cardiovascular-related hospitalization ), with a Win Ratio of 1.8 - Acoramidis.